DGEN TECHNOLOGIES ACQUIRES EXCLUSIVE LICENCE TO HUMANOS ARTIFICIAL INTELLIGENCE TECHNOLOGY

VANCOUVER, BC, Nov. 12, 2026 /CNW/ -- DGEN Technologies Corp. (CSE: DGEN) ("DGEN" or the "Company") is pleased to announce that it has entered into a licence agreement dated November 12, 2026 (the "Licence Agreement") with HumanOS Technologies Inc. ("HumanOS"), an arm's length company, pursuant to which HumanOS has granted the Company an exclusive and irrevocable licence (the "Licence") to its artificial intelligence software, automation technology and related assets (the "Transaction").

The licensed assets include the software, source code, systems, platforms and tools developed and operated by HumanOS under the "HumanOS" name, including the HumAIn, Matspace, Media Studio and Automation Lab products and the HumanOS scan tool, together with the HumanOS trade name, the 1humanos.com domain and associated websites and social media accounts, client and customer lists (names and contact details only) and related information and documentation (collectively, the "Licensed Assets"). The Licence permits the Company and its affiliates to use, commercialize, further develop and sublicense the Licensed Assets. HumanOS retains ownership of the Licensed Assets, while any improvements to the Licensed Assets developed by or for the Company will be owned by the Company.

In consideration for the Licence, the Company will issue an aggregate of 4,000,000 common shares in the capital of the Company (the "Consideration Shares") at a deemed price of $0.25 per Consideration Share and 4,000,000 common share purchase warrants (the "Consideration Warrants"). Each Consideration Warrant will be exercisable to acquire one common share of the Company at an exercise price of $0.32 per share for a period of three years from the date of issuance. The Consideration Shares and Consideration Warrants, and any shares issued on exercise of the Consideration Warrants, will be subject to a statutory hold period of four months and one day from the date of issuance in accordance with applicable securities laws.

Closing of the Transaction, including the issuance of the Consideration Shares and Consideration Warrants ("Closing"), remains subject to the approval of the Canadian Securities Exchange (the "CSE") and the satisfaction of certain other conditions, including the delivery to the Company of the source code and other materials comprising the Licensed Assets. Closing is expected to occur in the coming week or weeks. No finder's fees are payable in connection with the Transaction.

About DGEN Technologies Corp.

DGEN Technologies Corp. is a Vancouver-based technology company developing a cloud-based payment platform intended to integrate point-of-sale, kiosk and mobile payment systems into a unified and scalable solution. The Company's platform is currently in beta stage and not yet in use by any business, and has not yet been commercialized or generated revenue.

The CSE has not reviewed, approved, or disapproved, and does not accept responsibility for the adequacy or accuracy of the contents of this news release.

Forward-Looking Information

This news release contains "forward-looking information" within the meaning of applicable Canadian securities laws, including, without limitation, statements with respect to: the Transaction, including the anticipated timing of Closing, the receipt of CSE approval and the satisfaction of the other conditions to Closing; the issuance of the Consideration Shares and Consideration Warrants; the delivery of the Licensed Assets to the Company; the Company's ability to use, develop, commercialize and sublicense the Licensed Assets; the development, functionality, commercialization and market adoption of the Company's platform and its ability to generate revenue; and the future plans and objectives of the Company. Forward-looking information is based on management's current expectations, estimates, projections, beliefs and assumptions as of the date of this news release, including assumptions that CSE approval will be obtained on a timely basis; that the other conditions to Closing will be satisfied; that HumanOS will deliver the Licensed Assets as contemplated by the Licence Agreement; that HumanOS holds the rights necessary to grant the Licence; that the Licensed Assets will perform as expected and can be integrated into the Company's business; that the Company will have access to sufficient financing and personnel; and that there will be no material adverse changes in applicable regulatory requirements.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking information. These risks and uncertainties include, but are not limited to: the possibility that CSE approval is not obtained or the other conditions to Closing are not satisfied, and that the Transaction is not completed on the terms or timeline contemplated, or at all; the possibility that HumanOS does not deliver the Licensed Assets as contemplated; risks relating to the ownership, validity and enforceability of intellectual property rights in the Licensed Assets, including third-party claims; the possibility that the Licensed Assets do not perform as expected or cannot be successfully integrated, developed or commercialized; dilution resulting from the issuance of the Consideration Shares and the exercise of the Consideration Warrants; the fact that the Company's platform remains in beta stage, has not been commercialized and has not generated revenue; risks relating to the Company's early stage of development; risks associated with the development, commercialization and market adoption of the platform; competition from established technology providers; reliance on third-party contractors and service providers; additional financing and dilution risks; market volatility; regulatory, compliance, cybersecurity and data privacy risks; and the other risks described in the Company's public disclosure record available under its profile on SEDAR+ at www.sedarplus.ca. Readers are cautioned not to place undue reliance on forward-looking information, which speaks only as of the date of this news release. Except as required by applicable securities laws, the Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

SOURCE DGEN Technologies Corp.

For further information, please contact: DGEN TECHNOLOGIES CORP., Cole Goodwin, Chief Executive Officer, Tel. No.: (604)-364-3443, Email: [email protected]